Literature DB >> 22057380

Medical management of ischemic stuttering priapism: a contemporary review of the literature.

Helen R Levey1, Omer Kutlu, Trinity J Bivalacqua.   

Abstract

Priapism is defined as a prolonged and persistent erection of the penis without sexual stimulation. This is a poorly understood disease process with little information on the pathophysiology of this erectile disorder. Complications from this disorder are devastating due to the irreversible erectile damage and resultant erectile dysfunction (ED). Stuttering priapism, though relatively rare, affects a high prevalence of men with sickle-cell disease (SCD) and presents a challenging problem with guidelines for treatment lacking or resulting in permanent ED. The mechanisms involved in the development of priapism in this cohort are poorly characterized; therefore, medical management of priapism represents a therapeutic challenge to urologists. Additional research is warranted, so we can effectively target treatments for these patients with prevention as the goal. This review gives an introduction to stuttering priapism and its clinical significance, specifically with regards to the patient with SCD. Additionally, the proposed mechanisms behind its pathophysiology and a summary of the current and future targets for medical management are discussed.

Entities:  

Mesh:

Year:  2011        PMID: 22057380      PMCID: PMC3753435          DOI: 10.1038/aja.2011.114

Source DB:  PubMed          Journal:  Asian J Androl        ISSN: 1008-682X            Impact factor:   3.285


  70 in total

1.  Favorable response to intrathecal, but not oral, baclofen of priapism in a patient with spinal cord injury.

Authors:  Giangaetano D'Aleo; Carmela Rifici; Markus Kofler; Leopold Saltuari; Placido Bramanti
Journal:  Spine (Phila Pa 1976)       Date:  2009-02-01       Impact factor: 3.468

Review 2.  Priapism: current principles and practice.

Authors:  Arthur L Burnett; Trinity J Bivalacqua
Journal:  Urol Clin North Am       Date:  2007-11       Impact factor: 2.241

3.  Oral ketoconazole for prevention of postoperative penile erection: a placebo controlled, randomized, double-blind trial.

Authors:  Brian J DeCastro; Raymond A Costabile; Leah P McMann; Andrew C Peterson
Journal:  J Urol       Date:  2008-03-18       Impact factor: 7.450

Review 4.  Stuttering priapism--a review of the therapeutic options.

Authors:  A Muneer; S Minhas; M Arya; D J Ralph
Journal:  Int J Clin Pract       Date:  2008-05-08       Impact factor: 2.503

Review 5.  Adenosine signaling, priapism and novel therapies.

Authors:  Yingbo Dai; Yujin Zhang; Prasad Phatarpekar; Tiejuan Mi; Hong Zhang; Michael R Blackburn; Yang Xia
Journal:  J Sex Med       Date:  2009-03       Impact factor: 3.802

Review 6.  Sickle cell disease and pulmonary hypertension in Africa: a global perspective and review of epidemiology, pathophysiology, and management.

Authors:  Zakari Y Aliyu; Gregory J Kato; James Taylor; Aliyu Babadoko; Aisha I Mamman; Victor R Gordeuk; Mark T Gladwin
Journal:  Am J Hematol       Date:  2008-01       Impact factor: 10.047

7.  Sickle cell disease status and outcomes of African-American men presenting with priapism.

Authors:  Nelson Bennett; John Mulhall
Journal:  J Sex Med       Date:  2008-02-25       Impact factor: 3.802

Review 8.  Insights of priapism mechanism and rationale treatment for recurrent priapism.

Authors:  Jiuhong Yuan; Rowena Desouza; O Lenaine Westney; Run Wang
Journal:  Asian J Androl       Date:  2008-01       Impact factor: 3.285

9.  Establishment of a transgenic sickle-cell mouse model to study the pathophysiology of priapism.

Authors:  Trinity J Bivalacqua; Biljana Musicki; Lewis L Hsu; Mark T Gladwin; Arthur L Burnett; Hunter C Champion
Journal:  J Sex Med       Date:  2009-06-11       Impact factor: 3.802

10.  Intermittent priapism in degenerative lumbar spinal stenosis: case report.

Authors:  Tufan Cansever; Erdinç Civelek; Altay Sencer; Aykut Karasu; Inan Turantan
Journal:  Turk Neurosurg       Date:  2007-10       Impact factor: 1.003

View more
  14 in total

1.  Sexual dysfunction: First EAU priapism treatment guidelines published.

Authors:  Maarten Albersen; Trinity J Bivalacqua
Journal:  Nat Rev Urol       Date:  2014-01-28       Impact factor: 14.432

Review 2.  Management of priapism: an update for clinicians.

Authors:  Helen R Levey; Robert L Segal; Trinity J Bivalacqua
Journal:  Ther Adv Urol       Date:  2014-12

Review 3.  Contemporary best practice in the evaluation and management of stuttering priapism.

Authors:  Georgios Kousournas; Asif Muneer; David Ralph; Evangelos Zacharakis
Journal:  Ther Adv Urol       Date:  2017-07-04

4.  [Diagnosis and management of priapism].

Authors:  A Kaminsky; H Sperling
Journal:  Urologe A       Date:  2015-05       Impact factor: 0.639

Review 5.  [Priapism: Current diagnostics and therapy].

Authors:  B Schwindl; T Bschleipfer; T Klotz
Journal:  Urologe A       Date:  2015-11       Impact factor: 0.639

Review 6.  Unsatisfactory outcomes of prolonged ischemic priapism without early surgical shunts: our clinical experience and a review of the literature.

Authors:  Da-Chao Zheng; Hai-Jun Yao; Ke Zhang; Ming-Xi Xu; Qi Chen; Yan-Bo Chen; Zhi-Kang Cai; Mu-Jun Lu; Zhong Wang
Journal:  Asian J Androl       Date:  2012-08-27       Impact factor: 3.285

7.  [Emergencies of the external genital area].

Authors:  A Kaminsky; H Sperling
Journal:  Urologe A       Date:  2016-04       Impact factor: 0.639

8.  [Prophylaxis of recurring low-flow priapism : Experimental botulinum neurotoxin injection into the ischiocavernosus muscle].

Authors:  G Reichel; A Stenner
Journal:  Urologe A       Date:  2018-01       Impact factor: 0.639

9.  Prostate cancer risk after anti-androgen treatment for priapism.

Authors:  Tabitha Goetz; Arthur L Burnett
Journal:  Int Urol Nephrol       Date:  2013-10-18       Impact factor: 2.370

10.  New views on ultrasonography in high-flow priapism, with typical cases.

Authors:  Wen-Long Xie; Yang Liu; Ying Che; Ke-Nan Wang; Tao Jiang
Journal:  Asian J Androl       Date:  2021 Jul-Aug       Impact factor: 3.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.